Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More
AUROBINDO PHARMA | WOCKHARDT | AUROBINDO PHARMA/ WOCKHARDT |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 18.5 | -79.6 | - | View Chart |
P/BV | x | 4.0 | 1.8 | 227.8% | View Chart |
Dividend Yield | % | 0.3 | 0.0 | 11,981.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
WOCKHARDT Mar-18 |
AUROBINDO PHARMA/ WOCKHARDT |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 1,012 | 82.0% | |
Low | Rs | 527 | 532 | 99.2% | |
Sales per share (Unadj.) | Rs | 333.9 | 355.9 | 93.8% | |
Earnings per share (Unadj.) | Rs | 40.4 | -60.3 | -67.0% | |
Cash flow per share (Unadj.) | Rs | 51.8 | -46.8 | -110.7% | |
Dividends per share (Unadj.) | Rs | 2.50 | 0.01 | 25,000.0% | |
Dividend yield (eoy) | % | 0.4 | 0 | 28,433.8% | |
Book value per share (Unadj.) | Rs | 237.1 | 257.8 | 92.0% | |
Shares outstanding (eoy) | m | 585.91 | 110.63 | 529.6% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 2.2 | 93.7% | |
Avg P/E ratio | x | 16.8 | -12.8 | -131.3% | |
P/CF ratio (eoy) | x | 13.1 | -16.5 | -79.4% | |
Price / Book Value ratio | x | 2.9 | 3.0 | 95.6% | |
Dividend payout | % | 6.2 | 0 | -37,341.1% | |
Avg Mkt Cap | Rs m | 397,569 | 85,379 | 465.7% | |
No. of employees | `000 | 17.9 | 6.3 | 285.5% | |
Total wages/salary | Rs m | 25,849 | 9,371 | 275.8% | |
Avg. sales/employee | Rs Th | 10,956.9 | 6,295.0 | 174.1% | |
Avg. wages/employee | Rs Th | 1,447.7 | 1,498.3 | 96.6% | |
Avg. net profit/employee | Rs Th | 1,324.3 | -1,066.3 | -124.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 39,369 | 496.9% | |
Other income | Rs m | 1,553 | 1,202 | 129.2% | |
Total revenues | Rs m | 197,189 | 40,571 | 486.0% | |
Gross profit | Rs m | 39,519 | 18 | 215,953.0% | |
Depreciation | Rs m | 6,680 | 1,495 | 446.7% | |
Interest | Rs m | 2,626 | 2,555 | 102.8% | |
Profit before tax | Rs m | 31,767 | -2,830 | -1,122.7% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | -3,582 | 24.6% | |
Tax | Rs m | 7,269 | 257 | 2,828.2% | |
Profit after tax | Rs m | 23,645 | -6,669 | -354.6% | |
Gross profit margin | % | 20.2 | 0 | 43,457.6% | |
Effective tax rate | % | 22.9 | -9.1 | -251.9% | |
Net profit margin | % | 12.1 | -16.9 | -71.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 33,796 | 454.6% | |
Current liabilities | Rs m | 120,429 | 26,917 | 447.4% | |
Net working cap to sales | % | 17.0 | 17.5 | 97.2% | |
Current ratio | x | 1.3 | 1.3 | 101.6% | |
Inventory Days | Days | 135 | 79 | 170.4% | |
Debtors Days | Days | 64 | 89 | 71.4% | |
Net fixed assets | Rs m | 103,909 | 39,664 | 262.0% | |
Share capital | Rs m | 586 | 553 | 105.9% | |
"Free" reserves | Rs m | 138,322 | 27,968 | 494.6% | |
Net worth | Rs m | 138,908 | 28,522 | 487.0% | |
Long term debt | Rs m | 1,800 | 21,731 | 8.3% | |
Total assets | Rs m | 264,544 | 81,620 | 324.1% | |
Interest coverage | x | 13.1 | -0.1 | -12,181.2% | |
Debt to equity ratio | x | 0 | 0.8 | 1.7% | |
Sales to assets ratio | x | 0.7 | 0.5 | 153.3% | |
Return on assets | % | 9.9 | -5.0 | -197.0% | |
Return on equity | % | 17.0 | -23.4 | -72.8% | |
Return on capital | % | 23.8 | -7.7 | -310.6% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 9,807 | 992.3% | |
Fx outflow | Rs m | 40,589 | 1,789 | 2,269.3% | |
Net fx | Rs m | 56,727 | 8,019 | 707.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 684 | 2,370.0% | |
From Investments | Rs m | -28,768 | 6,302 | -456.5% | |
From Financial Activity | Rs m | 19,191 | -7,695 | -249.4% | |
Net Cashflow | Rs m | 6,656 | -664 | -1,002.5% |
Indian Promoters | % | 54.1 | 74.5 | 72.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.0 | 2.3 | 345.7% | |
FIIs | % | 27.7 | 7.7 | 359.7% | |
ADR/GDR | % | 0.0 | 0.1 | - | |
Free float | % | 10.2 | 15.4 | 66.2% | |
Shareholders | 69,601 | 67,757 | 102.7% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: ALEMBIC SUN PHARMA IPCA LABS FDC NEULAND LABS
Compare AUROBINDO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets ended on a flat note on Friday. Benchmark indices gave up early gains during closing hours on Friday as investors worried about the surge in Covid cases in the country
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More